By 2020, only 10.8% of adults aged 50 and older had completed both doses of the recombinant zoster vaccine,with 14.1% receiving at least one.

A study reveals that vitiligo significantly impacts quality of life and mental health in Japanese patients, highlighting the need for early psychological support.

The biosimilar market experienced 16 new approvals by early December 2025, marking significant expansion and introducing previously unavailable biosimilar drug classes to patients.

An analysis of patients with stage III colon patients found celecoxib improves survival only in those who are positive for circulating tumor DNA.

Teledermatology revolutionized skin care in 2025, enhanced access and efficiency through virtual tools and AI while addressing safety and trust concerns.

A study of more than 1 million UK medical records found that getting a flu vaccine between ages 40 and 50 did not increase Parkinson’s disease risk and was even associated with a lower estimated prevalence eight years later, suggesting a possible protective effect that warrants further research.

Medicare's first negotiated drug prices, effective January 2026, provide modest discounts, with limited savings for most beneficiaries and some unintended consequences.

A new Tufts study found that Medicare price negotiations on biologics with imminent biosimilars could lead to near-term savings, but greater savings are likely from biosimilar competition.